



A Carelon Company

GASTROENTEROLOGY ORDER SET

P: 877-365-5566 | **F:** 855-889-2946

PATIENT INFORMATION

Fax completed form, insurance information, and clinical documentation to 855-889-2946

Name:		DOB:	Gender: <input type="checkbox"/> Female <input type="checkbox"/> Male	
Address:		City:	State:	ZIP:
Phone:	Email:	Height:	<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight: <input type="checkbox"/> lbs. <input type="checkbox"/> kg
Allergies:				

Diagnosis Code ICD-10 (required):	Diagnosis Description:
Patient Status: <input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy	Next Treatment Date:

PHYSICIAN INFORMATION

Prescriber Name:		Phone:	Fax:
Office Contact:		Email:	
Address:		City:	State: ZIP:
NPI #:	DEA#:	Tax ID:	

INSURANCE INFORMATION (or attach copy of cards)

Primary Insurance:	Policy #:	Group #:
Secondary Insurance:	Policy #:	Group #:

PRESCRIPTION INFORMATION (or attach a copy of the prescription)

Drug	Dosing	Refills
Cimzia (certolizumab pegol)	<input type="checkbox"/> 400mg subQ at weeks 0, 2, 4 and then every 4 weeks <input type="checkbox"/> _____ mg subQ every _____ weeks	<input type="checkbox"/> x1 year <input type="checkbox"/> _____
Entyvio (vedolizumab)	<input type="checkbox"/> 300mg IV at 0, 2, 6 weeks and then Q8 weeks <input type="checkbox"/> 300mg IV every 8 weeks <input type="checkbox"/> 300mg IV at 0 and 2 weeks (IV to subQ dosing)	<input type="checkbox"/> x1 year <input type="checkbox"/> _____
Skyrizi (risankizumab)	Initial infusion: <input type="checkbox"/> 600mg or <input type="checkbox"/> 1200mg IV at week 0, 4, and 8 weeks Maintenance*: <input type="checkbox"/> 180mg or <input type="checkbox"/> 360mg subQ at week 12, and every 8 weeks thereafter	<input type="checkbox"/> x1 year <input type="checkbox"/> _____
<input type="checkbox"/> Ustekinumab or ustekinumab biosimilar <small>(as required by patient's insurance)</small> <input type="checkbox"/> Do not substitute. Infuse the following ustekinumab product: _____	Initial infusion: <input type="checkbox"/> 260mg <input type="checkbox"/> 390mg <input type="checkbox"/> 520mg IV x 1 dose Maintenance*: <input type="checkbox"/> 90mg SQ 8 weeks after initial infusion and then every 8 weeks thereafter <i>For Paragon use only.</i> Brand: _____	<input type="checkbox"/> x1 year <input type="checkbox"/> _____
Omvo (mirikizumab)	Initial infusion: <input type="checkbox"/> 300mg or <input type="checkbox"/> 900mg IV at 0, 4, and 8 weeks Maintenance*: <input type="checkbox"/> 200mg or <input type="checkbox"/> 300mg subQ at week 12, then every 4 weeks	<input type="checkbox"/> x1 year <input type="checkbox"/> _____
Tremfya (guselkumab)	Initial infusion: 200mg IV at 0, 4, and 8 weeks Maintenance*: <input type="checkbox"/> 100mg subQ at week 16, then every 8 weeks thereafter OR <input type="checkbox"/> 200mg subQ at week 12, then every 4 weeks thereafter	<input type="checkbox"/> x1 year <input type="checkbox"/> _____
<input type="checkbox"/> Infliximab or infliximab biosimilar <small>(as required by patient's insurance)</small> <input type="checkbox"/> Do not substitute. Infuse the following infliximab product: _____	Dose: _____ mg/kg IV Frequency: <input type="checkbox"/> 0, 2, 6 then every 8 weeks <input type="checkbox"/> Every _____ weeks <i>For Paragon use only.</i> Brand: _____	<input type="checkbox"/> x1 year <input type="checkbox"/> _____

*SubQ maintenance doses are filled by Paragon Specialty Pharmacy as applicable

Premedication orders: Acetaminophen 1000mg 500mg PO, please choose one antihistamine:
 Diphenhydramine 25mg PO Loratadine 10mg PO Cetirizine 10mg PO Cetirizine 10mg IVP

Additional premedications: Solu-Medrol _____ mg IVP Solu-Cortef _____ mg IVP Other _____

Lab orders: _____ **Frequency:** Every infusion Other: _____

Yearly TB QFT Baseline HepBcAB total Required labs to be drawn by: Paragon Healthcare Referring Provider

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution. Dispense as written

PRESCRIBER SIGNATURE By signing this form and utilizing our services, you are authorizing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

X: _____ **Date:** _____

PATIENT INFORMATION

Name:

DOB:

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

- Include signed and completed order (MD/prescriber to complete page 1)
- Include patient demographic information and insurance information
- Include patient's medication list
- Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
 - For biologic orders, has the patient had a documented contraindication/intolerance or failed trial of a conventional therapy (i.e., 6MP, azathioprine)? Yes No
If yes, which drug(s)? _____
 - For biologic orders, does the patient have a contraindication/intolerance or failed trial to any other biologic (i.e., Humira, Stelara, Cimzia)? Yes No
If yes, which drug(s)? _____
- Include labs and/or test results to support diagnosis
- If applicable* - Last known biological therapy: _____ and last date received: _____. If patient is switching biologic therapies, please perform a wash-out period of _____ weeks prior to starting ordered biologic therapy.
- Other medical necessity: _____

REQUIRED PRE-SCREENING (BASED ON DRUG THERAPY)

- TB screening test completed within 12 months - attach results**
Required for: Cimzia, Infliximab, Stelara, Entyvio, Skyrizi, Omvoh, Tremfya
 Positive **Negative**
- Hepatitis B screening test completed (Hepatitis B surface antigen) - attach results**
Required for: Cimzia, Infliximab
 Positive **Negative**
- Liver function tests & bilirubin** Required for: Skyrizi, Omvoh

*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)